Richard D. Gill

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Lovelace Respiratory Research Institute provides biomedical research services. It conducts research and development of countermeasures to chemical, biological, nuclear, radiological, and explosive emerging and environmental threats to human health as well as advancing the diagnosis and treatment of mental illness and other brain disorders. The company was founded in 1947 and is headquartered in Albuquerque, NM.

Rittenhouse Ventures LLC (Rittenhouse Ventures) is a venture capital firm founded in 2006 by Saul Richter and Bruce Luehrs. The firm is headquartered in Philadelphia, Pennsylvania.

SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.

NABsys, Inc. developed DNA analysis sequencing platform. Its platform used solid-state nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The firm system was designed to set new standards for accuracy, speed and scalability, offering compelling advantages for the analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. The company was founded by Xinsheng Sean Ling, Leon N. Cooper and Barrett Bready in 2004 and was headquartered in Providence, RI.

Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.